Novartis Secures EU Approval for Rhapsido: A New Oral Option for Chronic Spontaneous Urticaria

Novartis Secures EU Approval for Rhapsido: A New Oral Option for Chronic Spontaneous Urticaria

By, Admin 28 April 2026

The treatment landscape for chronic spontaneous urticaria (CSU) just shifted. Novartis has secured European Commission approval for Rhapsido (remibrutinib), introducing the first oral targeted therapy for CSU in patients who do not respond adequately to H1-antihistamines.

This is not just another approval. It signals a move toward more convenient, mechanism-driven treatments in a disease area long dominated by symptomatic management.

Why This Approval Matters?

CSU is more than a skin condition. It is unpredictable, persistent, and often debilitating.

Patients experience:

  • Intense itching (pruritus)
  • Recurrent hives (wheals)
  • Deep tissue swelling (angioedema)
  • Sleep disruption and fatigue
  • Mental health burden, including anxiety and depression

Globally, CSU affects around 40 million people, with a higher prevalence in women and peak incidence between ages 20 and 40.

Despite its impact, treatment options have been limited—especially for patients who do not respond to standard antihistamines. That gap is exactly where Rhapsido positions itself.

What Makes Rhapsido Different?

Rhapsido (remibrutinib) is the first approved oral Bruton’s tyrosine kinase (BTK) inhibitor for CSU.

Unlike conventional therapies that broadly suppress symptoms, remibrutinib targets the underlying immune pathway.

Mechanism of Action

  • Inhibits the BTK pathway
  • Reduces histamine release from immune cells
  • Directly addresses the driver of hives and swelling

Key Advantages

  • Oral pill taken twice daily
  • No lab monitoring required
  • Fast onset of symptom relief
  • Targeted immune modulation

This combination of convenience and specificity sets it apart from injectable biologics and long-term steroid use.

Clinical Evidence: REMIX Trials

The approval is backed by robust Phase III data from the REMIX-1 and REMIX-2 trials.

Trial Design

  • Global, multicenter, randomized, double-blind, placebo-controlled
  • 925 patients with inadequate response to second-generation H1-antihistamines

Outcomes at Week 12

Remibrutinib demonstrated:

  • Significant reduction in itch severity
  • Decrease in hives
  • Improved weekly urticaria activity scores

Safety Profile

  • No lab monitoring required
  • Most common adverse events (≥3%):
    • Nasopharyngitis
    • Headache
    • Nausea
    • Abdominal pain
    • Mild bleeding events

The safety and convenience profile could make adherence easier compared to existing options.

Regulatory and Guideline Momentum

The European Commission approval follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency earlier in 2026.

Additionally, remibrutinib has already been incorporated into the 2026 International Guidelines for Urticaria management—an early signal of strong clinical acceptance.

Beyond Europe, remibrutinib is already approved in the United States and China for similar patient populations.

Pipeline Potential Beyond CSU

Novartis is not positioning remibrutinib as a single-indication drug. The broader strategy is clear: expand across immune-mediated diseases.

Ongoing development includes:

  • Chronic inducible urticaria (CIndU)
  • Food allergies
  • Hidradenitis suppurativa (HS)

Positive Phase III results in the RemIND trial for CIndU further strengthen its lifecycle potential. This suggests a platform approach built around BTK inhibition in immunology.

The Bigger Picture: A Shift Toward Targeted Oral Immunology

Rhapsido represents a larger trend in pharma:

  • Moving from symptom control to pathway-specific intervention
  • Replacing injectables with oral therapies where possible
  • Reducing monitoring burden to improve real-world adherence

For pharma companies, this also raises the bar. Future therapies in dermatology and allergy will increasingly be judged on convenience, speed of relief, and mechanistic precision.

Final Takeaway

Rhapsido’s EU approval is not just incremental progress. It marks a structural upgrade in how CSU is treated.

For patients, it offers:

  • A non-injectable alternative
  • Faster, targeted relief
  • Improved day-to-day disease control

For the industry, it reinforces a clear direction: oral, targeted, and patient-friendly therapies are no longer optional—they are the new benchmark.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!